Alternatives to baricitinib
2 same-class SPL records vs baricitinib - uses, FAERS reaction fields, and OTC/Rx flags from public FDA sources.
Brand: Olumiant
About baricitinib
Olumiant contains baricitinib. It is a medicine that can lower the activity of your immune system.
Used for: Olumiant treats rheumatoid arthritis in adults when other medicines have not worked well. Rheumatoid arthritis is a disease that causes pain, swelling, and stiffness in the joints. Olumiant can also be used to treat alopecia areata, a condition that causes patchy hair loss.
2 JAK Inhibitor peers (wide set)
tofacitinib
RxXeljanz
Xeljanz treats rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and ulcerative colitis in adults. It is also used to treat psoriatic arthritis and juvenile idiopathic arthritis in children 2 years and older. It is for people who have not responded well to TNF blockers. Do not use Xeljanz with other strong immunosuppressants.
upadacitinib
RxRinvoq
Rinvoq can treat rheumatoid arthritis, psoriatic arthritis, atopic dermatitis (eczema), ulcerative colitis, Crohn’s disease, ankylosing spondylitis, non-radiographic axial spondyloarthritis, polyarticular juvenile idiopathic arthritis, and giant cell arteritis. It is used when other medicines, like TNF blockers, have not worked well enough. For ulcerative colitis and Crohn's disease, you should have tried at least one other approved medicine before using Rinvoq if TNF blockers are not suitable for you.
baricitinib vs tofacitinib & upadacitinib · FAERS reaction fields
FAERS top-reaction field "Rheumatoid Arthritis" shows the widest count spread between baricitinib and tofacitinib, upadacitinib in this extract (18,445-report gap on that field). Counts are exposure-weighted submissions, not prevalence rates.
| Side Effect | baricitinib | tofacitinib | upadacitinib |
|---|---|---|---|
| Covid-19 | 439 | - | 3,131 |
| Rheumatoid Arthritis | 352 | 18,797 | 3,037 |
| Pulmonary Embolism | 294 | - | - |
| Pneumonia | 264 | - | 1,779 |
| Headache | 253 | 13,405 | 1,792 |
| Herpes Zoster | 237 | - | - |
| Death | 235 | - | 1,630 |
| Nausea | 226 | 9,949 | 1,567 |
"-" means no reports for that reaction. Report counts reflect total FAERS submissions, not prevalence rates.
baricitinib peer mix vs class inventory
Peer mix
0 OTC and 2 Rx SPL records in this peer set (2 total). Class inventory for JAK Inhibitor: 3 drugs.
Frequently Asked Questions
What same-class SPL records sit beside baricitinib? ▼
Reading a wide JAK Inhibitor peer set (2 records)
baricitinib (Olumiant) sits in a wide JAK Inhibitor peer set (2 of 2 class peers shown). Labeled indication field for baricitinib: Olumiant treats rheumatoid arthritis in adults when other medicines have not worked well.
Top FAERS reaction fields for baricitinib total 2,696 reports across 10 reactions, set beside tofacitinib, upadacitinib. Counts are exposure-weighted submissions, not per-patient risk.
Registry note: Therapeutic-class peer lists are registry indexes, not prescribing advice. This information is for educational purposes only and is not a substitute for professional medical advice. Do not stop or change your medication without talking to your doctor or pharmacist.
Field note for baricitinib: see also the generic vs brand label guide when reading Olumiant SPL strings.
Read our methodology - how this data is sourced, computed, and verified.